Esophageal Squamous Cell Carcinoma - Pipeline Insight, 2022

DelveInsight's, "Esophageal Squamous Cell Carcinoma - Pipeline Insight, 2022," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Esophageal Squamous Cell Carcinoma Understanding

Esophageal Squamous Cell Carcinoma: Overview

Esophageal Squamous Cell Carcinoma is the most common form of esophageal cancer worldwide. Although it is no longer the most common form of esophageal carcinoma in Western societies, ESCC continues to be the most prevalent type of esophageal cancer in the East, representing 90% of all cancers in most Asian, African, and Eastern European countries. Clinical management of ESCC remains challenging and the disease presently lacks approved targeted therapeutics. The average age of onset of ESCC is between the ages of 60 to 70 years and it is more frequently seen in males. It is usually asymptomatic until an advanced disease stage with common presenting symptoms being dysphagia (at first with solids then progressing to fluids) and weight loss. Less commonly odynophagia, hoarseness of voice, coughing, or chest pain can be presenting features. Tumors are typically found in the middle and the upper third of the esophagus. The exact etiology is unknown. Cigarette smoking and alcohol abuse are the principal risk factors. There is also an association with idiopathic achalasia (see this term), a motility disorder of the esophagus. Endoscopy and a biopsy will establish the diagnosis. For staging, a computed tomography (CT) scan of the neck, chest and abdomen, or CT combined with a positron emission tomography (CT-PET) scan will identify the primary tumor in most cases as well as any spread to the lymph nodes and organs such as the liver, lungs and bone. Endoscopic ultrasound (EUS), the combination of an ultrasound probe on an endoscope, is also increasingly used for staging, and is of particular value for early cancers. In upper or mid-esophageal tumors where there is a possibility of invasion of the airway (trachea or bronchi) a bronchoscopy may also be required. Treatment may be with curative intent when the disease is confined to the esophagus and even when local nodes of the primary tumor are involved, and when the patient is fit enough for treatment. Treatment with palliative intent, targeted on symptom control and quality of life, but not cure, is the mainstay of treatment when the disease is advanced or incurable, or the patient is unfit for therapy due to significant co-morbidities. The traditional treatment of ESCC is surgical resection; this is usually via a transthoracic resection, and occasionally by a neck incision.

"Esophageal Squamous Cell Carcinoma - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Esophageal Squamous Cell Carcinoma pipeline landscape is provided which includes the disease overview and Esophageal Squamous Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Esophageal Squamous Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Esophageal Squamous Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Esophageal Squamous Cell Carcinoma.
• In the coming years, the Esophageal Squamous Cell Carcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Esophageal Squamous Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Esophageal Squamous Cell Carcinoma treatment market. Several potential therapies for Esophageal Squamous Cell Carcinoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Esophageal Squamous Cell Carcinoma market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Esophageal Squamous Cell Carcinoma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Esophageal Squamous Cell Carcinoma Emerging Drugs Chapters

This segment of the Esophageal Squamous Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Esophageal Squamous Cell Carcinoma Emerging Drugs

• Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene's immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Currently, it is in Phase III stage of clinical trial evaluation to treat Esophageal Squamous Cell Carcinoma.

• Serplulimab: Shanghai Henlius Biotech

Serplulimab (novel anti-PD-1 mAb) is the first innovative monoclonal antibody (mAb) developed by Henlius. Shanghai Henlius Biotech, announced that the phase 3 clinical study ASTRUM-007 of HANSIZHUANG (serplulimab) independently developed by the company in combination with chemotherapy as a first-line treatment for patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC), met the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) in a planned interim analysis, evaluated by the Independent Data Monitoring Committee (IDMC).

Further product details are provided in the report……..

Esophageal Squamous Cell Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Esophageal Squamous Cell Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Esophageal Squamous Cell Carcinoma

There are approx. 50+ key companies which are developing the therapies for Esophageal Squamous Cell Carcinoma. The companies which have their Esophageal Squamous Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, BeiGene.

• Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Esophageal Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Esophageal Squamous Cell Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Esophageal Squamous Cell Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Esophageal Squamous Cell Carcinoma drugs.

Esophageal Squamous Cell Carcinoma Report Insights

• Esophageal Squamous Cell Carcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Esophageal Squamous Cell Carcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Esophageal Squamous Cell Carcinoma drugs?
• How many Esophageal Squamous Cell Carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Esophageal Squamous Cell Carcinoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Esophageal Squamous Cell Carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Esophageal Squamous Cell Carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BeiGene
• Shanghai Henlius Biotech
• CStone Pharmaceuticals
• Jiangsu HengRui Medicine Co., Ltd.
• AstraZeneca
• Servier
• Hoffmann-La Roche
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Sinocelltech Ltd.
• Eli Lilly and Company
• Ipsen
• Jacobio Pharmaceuticals Co., Ltd.
• Shire
• GlaxoSmithKline
• Keythera Pharmaceuticals (Australia) Pty Ltd
• Sunshine Lake Pharma Co., Ltd.
• Novartis Pharmaceuticals
• Sanofi
• Seagen Inc.
• Rapa Therapeutics LLC
• Incyte Corporation
• Atreca, Inc.
• Eli Lilly and Company
• Exelixis
• Symphogen A/S
• Bayer
• Eisai Inc.

Key Products

• Tislelizumab
• Serplulimab
• CS1001
• Camrelizumab
• Durvalumab
• Sym021
• E7766
• Spartalizumab
• Sym022
• Sym023
• Regorafenib
• INCB099318
• S095033
• RO7121661
• XB002
• LGK974
• Abemaciclib
• ladiratuzumab vedotin
• ATRC-101
• SGN-PDL1V
• RO7247669
• THOR-707
• Letetresgene Autoleucel
• TNO155
• Anlotinib Hydrochloride
• Larotinib
• SCT-I10A
• KF-0210
• SCT200
• Ramucirumab
• Cabozantinib
• JAB-3068
• Onivyde
• JAB-3312
• SGN-B6A
• RAPA-201